Noxopharm Signs licensing agreement with Hudson Institute for RNA technology
- Noxopharm (NOX) signs licensing agreement with Hudson Institute of Medical Research for its cutting-edge ribonucleic acid (RNA) technology
- The licence is subject to clinical trials and marketing approvals for both RNA drug discovery and mRNA vaccine manufacture
- RNA drugs, already under development by Hudson, will add to the existing Pharmorage assets
- RNA technology is seen as a key contributor for future drug and vaccine development
- On the market today, the company was in the grey and trading at 48.5 cents per share
